Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7531434 | 0.81 | MAPT (0.53) | RAB9AGAAMAPTMEN1KMT2A | |
| SCHEMBL8985182 | 0.79 | ALDH1A1 (0.42) | GAAMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31231920 | 0.77 | MEN1 (0.56) | RAB9AGAAMAPTMEN1KMT2A | |
| SCHEMBL10567833 | 0.77 | MEN1 (0.56) | RAB9AGAAMAPTMEN1KMT2A | |
| SCHEMBL2317686 | 0.75 | MAPT (0.56) | RAB9AGAAMAPTMEN1KMT2A | |
| SCHEMBL4076876 | 0.74 | MEN1 (0.53) | RAB9AGAAMAPTMEN1KMT2A | |
| SCHEMBL12123166 | 0.74 | MAPT (0.52) | GAAMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7710352 | 0.73 | MAPT (0.53) | RAB9AGAAMAPTMEN1KMT2A | |
| SCHEMBL1323274 | 0.73 | MAOB (0.54) | RAB9AMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24265378 | 0.72 | MAPT (0.57) | RAB9AGAAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896400-B1 | 18F OR 11C-LABELLED ALKYLTHIOPHENYL GUANIDINES FOR USE IN MEDICAL IMAGING | HAMMERSMITH IMANET LTD (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-8058311-B2 | Imaging 18F or 11C-labelled alkylthiophenyl guanidines | HAMMERSMITH IMANET LIMITED (GB) | 2011-11-15 | — | — | US | disclosed |
| US-20100143252-A1 | IMAGING 18F OR 11C-LABELLED ALKYLTHIOPHENYL GUANIDINES | GE HEALTHCARE LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| EP-1521741-B1 | IMAGING COMPOUNDS | HAMMERSMITH IMANET LTD (GB) | 2008-12-24 | — | — | EP | disclosed |
| US-7432397-B2 | Imaging compounds | HAMMERSMITH IMANET LTD. (GB) | 2008-10-07 | — | — | US | disclosed |
| EP-1896400-A1 | IMAGING 18F OR 11C-LABELLED ALKYLTHIOPHENYL GUANIDINES | Hammersmith Imanet, Ltd (GB) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006136846-A1 | IMAGING 18F OR 11C-LABELLED ALKYLTHIOPHENYL GUANIDINES | HAMMERSMITH IMANET LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| US-20050260125-A1 | e.g. (N-(2-chloro-5-(methylthio)phenyl)-N'-(3-methylthio)phenyl)-N'-[N-methyl-11C]-methylguanidine; in vivo diagnostic or imaging method such as PET for central nervous system (N-methyl-D-aspartate) receptors; stroke, brain or spinal chord trauma, epilepsy, Alzheimer's, and Huntington's diseases | GE HEALTHCARE LIMITED (GB) | 2005-11-24 | — | — | US | disclosed |
| EP-1521741-A1 | IMAGING COMPOUNDS | Hammersmith Imanet, Ltd (GB) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004007440-A1 | IMAGING COMPOUNDS | HAMMERSMITH IMANET LTD (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050260125-A1 | e.g. (N-(2-chloro-5-(methylthio)phenyl)-N'-(3-methylthio)phenyl)-N'-[N-methyl-11C]-methylguanidine; in vivo diagnostic or imaging method such as PET for central nervous system (N-methyl-D-aspartate) receptors; stroke, brain or spinal chord trauma, epilepsy, Alzheimer's, and Huntington's diseases | GLRA1, SHH, NMUR1 | RAB9A 295/4885GAA 3054/4885MAPT 121/4885 |
| US-20100143252-A1 | IMAGING 18F OR 11C-LABELLED ALKYLTHIOPHENYL GUANIDINES | SSTR3, GPR3, GALR3 | RAB9A 480/4885GAA 3453/4885MAPT 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.